PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.